Publications

In this section you will find a list of scientific publications relevant to the IBD community and in which EFCCA has been the co-author.

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients August, 2020 In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients. Read Study    

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey Patients with chronic diseases have experienced substantial changes to the routine management of their conditions during the coronavirus disease 2019 (COVID-19) pandemic.1,2 Although insights into the management of patients with inflammatory bowel disease (IBD) during the outbreak have been described,3...

Quality of Care Standards in Inflammatory Bowel Diseases

Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn’s and Colitis Organisation [ECCO] Position Paper February, 2020 The management of inflammatory bowel disease [IBD] is complex, and requires tight control of disease activity, close monitoring to avoid treatment side effects, health care professionals with expertise in IBD, and an interdisciplinary, holistic approach...

The Future of Biosimilars

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases February, 2020 Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can...

The Socioeconomic Impact of Living With Ulcerative Colitis

43 The Socioeconomic Impact of Living With Ulcerative Colitis: A Burden of Illness Study October, 2019 The living with Ulcerative Colitis (UC), identifying the socioeconomic burden in Europe (LUCID) study was a descriptive, retrospective, cross-sectional, European, multi-site, bottom-up Burden of Illness research study carried out by HCD Economics and the University of Chester in...

The Impact of Ulcerative Colitis on Quality of Life and Productivity Across Europe

744 The Impact of Ulcerative Colitis on Quality of Life and Productivity Across Europe: A Burden of Illness Study October, 2019 The Living with Ulcerative Colitis: Identifying the socioeconomic burden in Europe (LUCID) study was a descriptive, retrospective, cross-sectional, European (France, Germany, Italy, Spain, United Kingdom, Denmark, Norway, Poland, Romania and Turkey), multi-site...

Changes in inflammatory bowel disease patients’ perspectives on biosimilars

Changes in inflammatory bowel disease patients’ perspectives on biosimilars: A follow-up survey October, 2019 The aim of this survey was to find out whether the perspectives of patients with inflammatory bowel disease concerning biosimilars have changed since the publication of our last survey carried out in 2014–2015. Read Study     

Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease

Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies October, 2018 The increasing prevalence of inflammatory bowel disease and the high costs associated with biologic therapies suggest that biologics with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment...

Preparing for the incoming wave of biosimilars in oncology

Preparing for the incoming wave of biosimilars in oncology September, 2018 With the imminent arrival of oncology biosimilars in the therapeutic paradigm, stakeholders including a clinician, specialist nurse, patient advocate, regulator and economist provide their perspective on optimising the uptake of these new agents in the treatment of cancer. A number of key messages emerge, based on...

Iron deficiency with or without anaemia in IBD

P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey Iron deficiency (ID) and iron deficiency anaemia (IDA) are conditions frequently observed in patients with inflammatory bowel disease (IBD) and require appropriate treatment. This study investigated patient and physician perspectives...